The factors possibly affecting the collection of peripheral blood stem cells (PBSC) were evaluated in 104 de novo acute leukemia patients (66 myeloid and 38 lymphoblastic leukemias) in first cytological complete remission (CR); all patients achieved CR after first-line induction chemotherapy. The acute myeloid leukemia patients (AML) were given consolidation-mobilization chemotherapy with cytarabine, and daunoblastin or mitoxantrone or idarubicin; the acute lymphoblastic leukemia patients (ALL) were given consolidation-mobilization chemotherapy with cytarabine and etoposide. In all patients, the collection of PBSC was performed during recovery after giving consolidation chemotherapy and granulocyte colony-stimulating factor (G-CSF). Two main groups were considered according to the CD34 þ cells Â 10 6 /kg b.w. collected, that is, poor mobilizers (PM), with a collection of o2 Â 10 6 /kg and good mobilizers, with a collection of 42 Â 10 6 /kg. Of 104 patients, 27 (25.9%) were PM; 20/27 had AML and 7/27 had ALL. At multivariate analysis, a lower CD34 þ cells count premobilization chemotherapy (CD34 steady state), the presence of FUO (fever of unknown origin) or infection, and a lower number of CD34 þ cells on the first day of collection correlated with poor mobilization. These results may enable early recognition of patients who may have poor mobilization, and aid selection of patients for different mobilization regimens.
The factors possibly affecting the collection of peripheral blood stem cells (PBSC) were evaluated in 104 de novo acute leukemia patients (66 myeloid and 38 lymphoblastic leukemias) in first cytological complete remission (CR); all patients achieved CR after first-line induction chemotherapy. The acute myeloid leukemia patients (AML) were given consolidation-mobilization chemotherapy with cytarabine, and daunoblastin or mitoxantrone or idarubicin; the acute lymphoblastic leukemia patients (ALL) were given consolidation-mobilization chemotherapy with cytarabine and etoposide. In all patients, the collection of PBSC was performed during recovery after giving consolidation chemotherapy and granulocyte colony-stimulating factor (G-CSF). Two main groups were considered according to the CD34 þ cells Â 10 6 /kg b.w. collected, that is, poor mobilizers (PM), with a collection of o2 Â 10 6 /kg and good mobilizers, with a collection of 42 Â 10 6 /kg. Of 104 patients, 27 (25.9%) were PM; 20/27 had AML and 7/27 had ALL. At multivariate analysis, a lower CD34 þ cells count premobilization chemotherapy (CD34 steady state), the presence of FUO (fever of unknown origin) or infection, and a lower number of CD34 þ cells on the first day of collection correlated with poor mobilization. These results may enable early recognition of patients who may have poor mobilization, and aid selection of patients for different mobilization regimens. transplants are associated with a shorter period of aplasia and lower transplant-related mortality. 5, 6 PBSC are usually collected by apheresis during the recovery phase following chemotherapy plus granulocyte-colony-stimulating factor (G-CSF). A significant correlation between sustained hematologic engraftment and the quantity of reinfused CD34 þ cells has been reported, indicating that collection of CD34 þ cells is likely to be crucial for safe engraftment. [7] [8] [9] [10] The quantity of PBSC to be infused to achieve a prompt recovery post transplant remains controversial, but at least 2 Â 10 6 /kg CD34 þ cells are usually required in autologous stem cell grafts to ensure hematopoietic recovery after myeloablative chemotherapy. [9] [10] [11] The number and type of premobilization chemotherapy or radiotherapy sessions, patient age and marrow involvement have been reported to affect mobilization in lymphoma, myeloma and cancer patients. [12] [13] [14] [15] [16] [17] [18] However, data regarding PBSC collection in acute leukemia patients are limited. [19] [20] [21] The purpose of this study was to identify CD34 cell mobilization factors (diagnosis, age, sex, CD34 cell count preconsolidation chemotherapy, type of chemotherapy, infections or fever of unknown origin (FUO), CD34 þ cells in the peripheral blood, white blood cells (WBC), mononuclear cells (MNC) on the first day of collection) in a series of 152 procedures performed on 104 de novo acute leukemia patients who achieved cytological complete remission (CR) after one cycle of chemotherapy.
Patients and methods

Patient population
From February 1990 to March 2002, 104 patients with de novo acute leukemia in first cytological CR were eligible for consolidation-mobilization chemotherapy plus G-CSF, and underwent peripheral blood stem cell harvest; of these patients (50 males and 54 females, aged 15-61 years, median 40 years), 66 had acute myelogenous leukemia (AML) and 38 had acute lymphoblastic leukemia (ALL). The patient characteristics are listed in In all patients, G-CSF was administered subcutaneously at a dose of 5 mg/kg daily, starting 10 days after the start of chemotherapy and continuing until the day before the apheresis. PB CD34 þ cell measurements were performed during the recovery phase after chemotherapy when a white blood count of 42 Â 10 9 /l was reached. Immediately prior to PBSC collection procedures, the PB with blood cell (WBC), MNC and CD34 þ counts was determined and correlated with the CD34 þ harvested.
PBCS were collected using blood cell separators CS3000 þ (Baxter-Fenwal, Deerfield, IL, USA) using a small-volume collection chamber; blood was collected via a central venous access device (60 patients) or from peripheral veins (44 patients), and a median of 8 l of blood was processed per apheresis. In all, 48 patients underwent one apheresis and 56 two apheresis procedures.
CD34 enumeration was performed on viable cells with a dual-platform version of the ISHAGE protocol; 22 briefly, the WBC were measured with an automated hematology analyzer and, if necessary, samples were diluted; 100 ml aliquots of the sample, containing between 5 Â 10 6 and 10 Â 10 6 cells, were incubated for 30 min at 41C with 10 ml of phycoerythrin (PE)-conjugated anti-CD34 (HPCA-2), 10 ml of fluorescein isothiocyanate (FITC)-conjugated anti-CD45 (2D1) (BD Biosciences) and 20 ml of 7-aminoactinomycin D (final concentration 1 mg/ml). After incubation, the red cells were lysed and cells were analyzed by fluorescenceactivated cell sorting (FACScan, Becton Dickinson) using the CellQuest Software.
Statistical analysis
The clinical characteristics of the two groups of patients, good mobilizers (GM) and poor mobilizers (PM), were compared using two-tailed Fisher's exact test for categorical variables and Student's t-test or the Mann-Whitney test for continuous variables. Pearson's test was used to correlate the CD34 steady state and CD34 at the first day of apheresis with the number of CD34 þ cells collected. The binary logistic regression model was used to analyse parameters found to be statistically significant at univariate analysis. Only P-values o0.05 were considered statistically significant. All the statistical analyses were carried out using the Statistical Package for Social Sciences (SPSS) package, version 11.0 for Windows.
Results
Correlations between the number of PBSC collected and patient diagnosis, sex, CD34 þ cells in the peripheral blood premobilization chemotherapy (CD34 þ steady state), chemotherapy, FUO or clinically or microbiologically documented infection during the neutropenic phase after consolidation chemotherapy, WBC, MNC and CD34 þ blood cells at the first day of collections were determined by multivariate analysis. According to the total collected CD34 þ cells Â 10 6 /kg b.w., two main groups were considered that is, PM, with a collection of o2 Â 10 6 /kg (27/104 pts, 25.9%), and GM, with a collection of 42 Â 10 6 /kg (77/104 pts, 74.1%) ( Table 2 ). There was no /l in GM and PM, respectively), MNC at the first day of collection (2.5 Â 10 9 vs 1.8 Â 10 9 /l in GM and PM). In the GM group, 56 patients underwent one apheresis and 21 patients underwent two apheresis procedures; all 27 PM patients underwent two apheresis procedures. No large-volume leukapheresis was done. The median of peripheral blood processed was 10 and 15 l in GM and PM, respectively. No significant differences in terms of PM were observed in patients treated with DNR or MITOX or IDA (19.2% in the DNR group vs 30% in the MITOX group vs 25% in the IDA group were PM). The median percentage of CD34 premobilization chemotherapy was 0.08 (range 0.02-0.19%) vs 0.02 (0.001-0.02%) in GM and PM, respectively; this translated into a median concentration of 6 Â 10 6 /l (range 4-10) vs 1 (range 0-5) in GM and PM, respectively (Po0.05). A correlation analysis showed that steady-state PB CD34 þ cells can reliably assess the CD34 þ cell yield in mobilized PB (Po0.05; r ¼ 0.77) (Figure 1 ). When grouped according to diagnosis, patients with ALL showed a higher baseline CD34 þ cell count than AML patients (7 vs 3 Â 10 6 /l in ALL and AML, respectively). In AML patients, no differences were found between the two groups (GM and PM), as regards the time from starting mobilization chemotherapy until apheresis (18 vs 19 days), the time from starting mobilization chemotherapy until recovery of neutrophils (17 vs 19 days) and the time between starting induction therapy and starting mobilization chemotherapy (48 vs 50 days); also, in ALL patients, no differences were found between the two groups (GM and PM), as regards the time from starting mobilization chemotherapy until apheresis (14 vs 15 days), the time from starting mobilization chemotherapy until recovery of neutrophils (13 vs 15 days), and the time between starting induction therapy and starting mobilization chemotherapy (48 vs 50 days). The median number of CD34 þ cells at the first day of apheresis was also higher in GM vs PM (160 vs 12 Â 10 6 /l) (Po0.001); the number of CD34 þ cells in the peripheral blood on the first day of apheresis was strongly correlated with the yields of CD34 in the relative harvest (r ¼ 0.81, Po0.001) (Figure 2) . A value below 20 Â 10 6 /l CD34 was associated with an 85% probability of PM and a value above 60 Â 10 6 /l CD34 was associated with a 90% probability of GM. As regards FUO or clinically or microbiologically documented infection during the neutropenic phase after consolidation chemotherapy, we found that FUO or infection adversely affected mobilization (of the patients with FUO or infection, 25/30 or 83.3% were PM) (Po0.005). In the PM group with fever (25 patients), there were 18 FUO and seven microbiologically documented infections; in the GM group with fever (five patients), there were four FUO and one microbiologically documented infection. (20) 15 (75%) 5 (25%) AML treated with MITOX (20) 14 ( 
Discussion
There are few available data concerning mobilization of PBSC in acute leukemia (AL) patients. We analyzed 152 PBSC collections in 104 AL patients in order to identify the possible predictive factors of the CD34 þ cells collection; all patients had received only one cycle of induction chemotherapy and one cycle of consolidation-mobilization chemotherapy. We have shown that, in the majority of patients with AL (74.1%), a target quantity of 2 Â 10 6 /kg could be collected from the peripheral blood following G-CSF-supported consolidation chemotherapy; the threshold number of 2 Â 10 6 CD34 þ cells/kg was chosen on the basis of previous studies demonstrating rapid and sustained engraftment following reinfusion of this amount.
7-11 When consolidation-mobilization chemotherapy was started, the patients were in first cytological CR following one cycle of induction chemotherapy. The effect of patient age as a predictor of the PBSC collection content is not clear. Lower age was a significant factor in obtaining a larger number of CD34 þ cells in the collection of patients in one study, 7 but age was not related to collection efficiency in other studies; 17, 23 we did not find any correlation between sex or age of the patients and the yields achieved. In terms of diagnosis, 20/66 (30.3%) AML patients and 7/38 (18.4%) ALL patients were poor mobilizers; the role of previous stem cell damage from cytotoxic drugs is the likely explanation, 18, 19, 21, 23 as these ALL patients had been less heavily pretreated during induction chemotherapy than AML patients. In our experience, patients with ALL showed a higher baseline CD34 þ cell count preconsolidation chemotherapy than AML patients; this difference in the yield of CD34 þ cells may be related to significant differences in the hemopoietic reserve and individual sensitivity of the hemopoietic progenitor cells to chemotherapy-related toxicity. 17 Fruehauf et al 24 found that PBSC counts in Hodgkin and non-Hodgkin lymphoma, multiple myeloma and solid tumors during steady-state hemopoiesis enable estimation of the yield of mobilized PBSC after G-CSF-supported cytotoxic chemotherapy. In our experience in this group of 104 AL patients, a clear correlation was observed between the steady-state PB CD34 þ cell count and the outcome of mobilization; the median number of CD34 premobilization chemotherapy was higher in good than poor mobilizers (Po0.05). Highbaseline PB CD34 þ cells in AL patients predict a high stem cell yield after mobilization with chemotherapy and G-CSF, irrespective of diagnosis, age and type of chemotherapy. Other studies regarding lymphoma and solid tumor patients [25] [26] [27] reported a strong correlation between the absolute cell number of circulating CD34 þ on the day of apheresis and the number of CD34 þ cells collected; we also found this correlation in our 104 AL patients (Po0.001). In our report, the presence of clinically or microbiologically documented fever or infection was associated with poor mobilization (Po0.005); inflammatory cytokines with their negative effect on the proliferation of stem cells may have a role in this poor mobilization. [28] [29] [30] The number of prior cytotoxic chemotherapy cycles has been reported to adversely affect the yield of PBSC in lymphoma, myeloma and solid tumor patients, 12-16 but Jowitt et al 21 showed that the number of induction courses received, and thus exposure to cytotoxic agents received, made no significant difference to the subsequent CFU-GM content in the peripheral blood in AL patients. In our series, all patients had received only one line induction-chemotherapy and one consolidation-mobilization chemotherapy before the PBSC collection. The timing of PBSC collection is therefore crucial and should be envisaged following efficient in vivo depletion of leukemic cells, but still before the hemopoietic reserve is impaired. We conclude that the CD34 cell count in the steady state, the absence of fever or infection and the CD34 þ cells in the peripheral blood on the day of apheresis are reliable predictors of the success of PBCS collection. High-baseline PB CD34 þ cells in AL patients achieving CR after one chemotherapy cycle may predict a high stem cell yield after the first consolidation therapy and G-CSF. The routine determination of baseline PB CD34 þ cell counts may identify patient groups at risk of a poor stem cell yield, who would thus qualify for enrolment in clinical trials on different mobilization regimens. 
